NCT02575950View on ClinicalTrials.gov

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Acne Vulgaris
Interventions
DRUG

LEO43204

DRUG

Placebo

Trial Locations (1)

90717

Torrance Clinical Research Institute Inc., Lomita

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY